Nurix Therapeutics, Inc. (NRIX)
NASDAQ: NRIX · Real-Time Price · USD
16.03
-0.21 (-1.29%)
At close: Apr 10, 2026, 4:00 PM EDT
15.80
-0.23 (-1.43%)
After-hours: Apr 10, 2026, 6:57 PM EDT
Nurix Therapeutics Revenue
Nurix Therapeutics had revenue of $6.25M in the quarter ending February 28, 2026, a decrease of -66.12%. This brings the company's revenue in the last twelve months to $71.78M, up 27.23% year-over-year. In the fiscal year ending November 30, 2025, Nurix Therapeutics had annual revenue of $83.98M with 53.95% growth.
Revenue (ttm)
$71.78M
Revenue Growth
+27.23%
P/S Ratio
23.09
Revenue / Employee
$226,432
Employees
317
Market Cap
1.66B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Nov 30, 2025 | 83.98M | 29.43M | 53.95% |
| Nov 30, 2024 | 54.55M | -22.44M | -29.15% |
| Nov 30, 2023 | 76.99M | 38.36M | 99.31% |
| Nov 30, 2022 | 38.63M | 8.88M | 29.84% |
| Nov 30, 2021 | 29.75M | 11.93M | 66.95% |
| Nov 30, 2020 | 17.82M | -13.30M | -42.73% |
| Nov 30, 2019 | 31.12M | -6.33M | -16.91% |
| Nov 30, 2018 | 37.45M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Harmony Biosciences Holdings | 868.45M |
| Immunocore Holdings | 400.02M |
| Vericel | 276.26M |
| Iovance Biotherapeutics | 263.50M |
| Recursion Pharmaceuticals | 74.68M |
| Intellia Therapeutics | 67.67M |
| Oculis Holding AG | 1.51M |
NRIX News
- 4 days ago - Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 5 days ago - Nurix Therapeutics to Participate in Upcoming Investor Conference - GlobeNewsWire
- 19 days ago - Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting - GlobeNewsWire
- 2 months ago - Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update - GlobeNewsWire
- 3 months ago - Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases - GlobeNewsWire
- 3 months ago - Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition - GlobeNewsWire
- 4 months ago - Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition - GlobeNewsWire